Synairgen (LON:SNG) Trading Down 16.4% – Here’s Why

Synairgen plc (LON:SNG) shares dropped 16.4% on Tuesday . The company traded as low as GBX 2.01 ($0.03) and last traded at GBX 2.01 ($0.03). Approximately 606,426 shares were traded during mid-day trading, a decline of 77% from the average daily volume of 2,656,023 shares. The stock had previously closed at GBX 2.41 ($0.03).

Synairgen Stock Down 3.3 %

The company has a debt-to-equity ratio of 0.09, a current ratio of 6.77 and a quick ratio of 6.35. The business’s fifty day simple moving average is GBX 3.30 and its two-hundred day simple moving average is GBX 3.83. The company has a market cap of £4.68 million, a PE ratio of -77.53 and a beta of -2.23.

Synairgen Company Profile

Synairgen is a respiratory drug discovery and development company founded by University of Southampton Professors Stephen Holgate, Donna Davies and Ratko Djukanovic. The business, focused primarily on lung viral defence in asthma and COPD, uses its differentiating human biology BioBank platform and world-renowned international academic KOL network to discover and develop novel therapies for respiratory disease.

Synairgen is conducting a double blind, placebo-controlled clinical trial in COVID-19 patients (SG016).